Back to News
Market Impact: 0.2
Cantor Fitzgerald Initiates Coverage of Spero Therapeutics at Overweight
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Cantor Fitzgerald initiated coverage of Spero Therapeutics on October 28, 2026, with an Overweight recommendation. The article provides no price target or further rationale in the available text.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
SPRO0.45
More News
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up
- Intel plunges on a major guidance miss. What went wrong — and how to proceed
- FedEx Freight delivers a much-needed quarterly beat. Where we stand on shares now
- We're cutting our Amazon price target after a tough quarter. But it isn't all bad
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on